The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
 
Yunpeng Yang
No Relationships to Disclose
 
Yuangyuan Zhao
No Relationships to Disclose
 
Ting Zhou
No Relationships to Disclose
 
Gang Chen
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Feng Liu
No Relationships to Disclose
 
Zhigang Liu
No Relationships to Disclose
 
Song Qu
No Relationships to Disclose
 
Yu Lei
No Relationships to Disclose
 
Xiaozhong Chen
No Relationships to Disclose
 
Lizhu Lin
No Relationships to Disclose
 
Zhichao Fu
No Relationships to Disclose
 
Xiaojing Zhang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Zeyu Yang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Chuanpei Huang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Speakers' Bureau - AstraZeneca; BeiGene; HenRui; Innovent Biologics; Roche China
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)